Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (BRAIN-AF)

NCT02387229 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.

NCT NCT02387229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (BRAIN-AF)
Lead sponsor
Montreal Heart Institute
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2015
Completion date
May 18, 2024
Enrollment
1,238 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation